Kimberly Vanover

Kimberly is a highly accomplished neuropsychiatric and neurodegenerative drug discoverer and developer with over 25 years of industry experience. Most recently, Kimberly served as SVP, Clinical Development and SVP, Early Stage Clinical Development and Translational Medicine at Intra-Cellular Therapies, guiding Caplyta (lumateperone) from early development to approval. Prior to Intra-Cellular, Kimberly worked at Acadia Pharmaceuticals, playing a key role in the development of Nuplazid (pimavanserin). Kimberly received her PhD in Biopsychology from the University of Chicago and completed her post-doctoral training at the University of California – San Diego and Lederle Laboratories.